Arnon P. Kater — Amsterdam UMC research portal

5 (207) · € 22.50 · Auf Lager

Chronic lymphocytic leukemia presence impairs antigen-specific CD8+ T-cell responses through epigenetic reprogramming towards short-lived effectors

SARS-CoV-2 hyperimmune globulin for severely immunocompromised patients with COVID-19: a randomised, controlled, double-blind, phase 3 trial

Arnon KATER, Clinical Hematologist and senior investigator, MD, PhD, Academisch Medisch Centrum Universiteit van Amsterdam, Amsterdam, AMC, Department of Hematology

Tipping the balance: toward rational combination therapies to overcome venetoclax resistance in mantle cell lymphoma

Arnon KATER, Clinical Hematologist and senior investigator, MD, PhD, Academisch Medisch Centrum Universiteit van Amsterdam, Amsterdam, AMC, Department of Hematology

Ibrutinib sensitizes CLL cells to venetoclax by interrupting TLR9-induced CD40 upregulation and protein translation

Fourth mRNA COVID-19 vaccination in immunocompromised patients with haematological malignancies (COBRA KAI): a cohort study - eClinicalMedicine

Human CXCR5+PD‐1+ CD8 T cells in healthy individuals and patients with hematologic malignancies - Hofland - 2021 - European Journal of Immunology - Wiley Online Library

Human CXCR5+PD‐1+ CD8 T cells in healthy individuals and patients with hematologic malignancies - Hofland - 2021 - European Journal of Immunology - Wiley Online Library

Abraham GOORHUIS, Internist/Infectious Diseases specialist, M.D./ Ph.D.

G.J.C. ZWEZERIJNEN, Nuclear medicine physician, Master of Science, Amsterdam University Medical Center, Amsterdam, VUmc, Department of Nuclear Medicine and PET Research